RCKT

Over the past six months, Rocket Pharmaceuticals announced the sale of a Rare Pediatric Disease Priority Review Voucher for $180 million in April 2026. The stock experienced various changes, including a -1.09% change on May 7, 2026, a +1.00% change on May 28, 2026, a +3.38% increase on June 12, 2026, and a +9.65% rise on August 3, 2026. On August 10, 2026, after reporting Q2 2026 financial results, the stock saw a -3.85% change, followed by a -1.81% change on September 3, 2026. Key positive events included FDA alignment on the path to complete the pivotal Phase 2 trial of RP-A501 in Danon Disease on September 15, 2026, securing a strategic credit facility for up to $150 million from Hercules Capital on October 6, 2026, and further positive clinical updates for RP-A501 on October 7, 2026, which led Cantor Fitzgerald to reiterate an "Overweight" rating. Goldman Sachs upgraded RCKT from "Sell" to "Neutral" on October 8, 2026, due to encouraging RP-A501 updates. Over the last year, the stock price decreased by 22%, and in the past month, it experienced a -35.8% change, trading between a 52-week high of $5.45 and a 52-week low of $2.42.